### Table of Contents

I. Background
   A. [Summary of Dissolvable Tobacco Products references](#) from the Family Smoking Prevention and Tobacco Control Act
   B. [Charter of the Tobacco Products Scientific Advisory Committee](#)

II. July 21-22, 2011 Tobacco Products Scientific Advisory Committee (TPSAC)
   A. [Federal Register Notice](#)
   B. [TPSAC Committee Roster](#)
   C. [Meeting Roster](#)
   D. [Final Agenda](#)
   E. Background Materials
      1. [FDA Summary Memorandum](#)
      2. Dissolvables References
      3. [Request to RJR for Information – February 1, 2010](#)
      4. [Request to Star for Information – February 1, 2010](#)
      5. [DRAFT Questions to Committee on Dissolvables](#)
      6. [Request for Information from Industry 904(b) (June 10, 2011)](#)
      7. [Industry Presentation Topics](#)
      8. [Federal Register Notice – Request for Comments to Docket](#)
      9. [Comments submitted to Docket](#)
      10. [Written Public Submissions](#)
      11. Submissions from Industry
          a) [RJR Background Information](#)
          b) [Star Background Information](#)
      F. Presentations from FDA
         1. [Dissolvable Tobacco Products- David L. Ashley, Ph.D., Director, Office of Science, FDA/CTP](#)
         2. [Process for the Report- Karen Templeton-Somers, Ph.D., Office of Science, FDA/CTP](#)
         3. [Dissolvable Tobacco Products- Sarah E. Evans, Ph.D., Office of Science, FDA/CTP](#)
G. Presentations from the Tobacco Industry
   1. Marketing and Consumer Perceptions
      a) Star Scientific - Curtis Wright, M.D., M.P.H., Senior Vice President & Clinical Director, Rock Creek Pharmaceuticals
      b) R. J. Reynolds Tobacco Company - Aaron P. Williams, Ph.D., Vice President, Smokeless Product Development, R. J. Reynolds
   2. Abuse Liability and Health Risks
      a) R. J. Reynolds Tobacco Company - Charles D. Garner, Ph.D. Senior Director, Regulatory Oversight, R. J. Reynolds
      b) Star Scientific - Curtis Wright, M.D., M.P.H., Senior Vice President & Clinical Director, Rock Creek Pharmaceuticals
   3. Initiation and Cessation
      a) Star Scientific - Curtis Wright, M.D., M.P.H. Senior Vice President & Clinical Director, Rock Creek Pharmaceuticals
      b) R. J. Reynolds Tobacco Company - Geoffrey M. Curtin, Ph.D., Principal Scientist/Director, Regulatory Oversight, R. J. Reynolds

H. Open Public Hearing
   1. Elaine Keller - The Consumer Advocates for Smoke-free Alternatives Association
   2. Wallace Pickworth - Battelle
   3. James E. Dillard, III - Altria Client Services
   5. Gregory N. Connolly, D.M.D., M.P.H.- Harvard School of Public Health

I. Discussion and Recommendations from July 21-22, 2011 Meeting
   1. Questions for Discussion
   2. Transcripts
      a) July 21, 2011
      b) July 22, 2011
   3. Webcast

J. Final Summary Minutes